Charles River And Quotient Sciences Collaboration

There are many challenges and considerations that drug developers face when bridging from early drug discovery to pre-clinical and onward toward the clinic. At this early stage in the development process, it is critical to partner with experienced service providers who can remove hurdles, provide technical expertise, and work together to seamlessly transition your molecule to the next phase of development.

The collaboration between Charles River and Quotient Sciences offers customers unique integrated programs that bridge molecules from early discovery to proof of concept (POC) and beyond. This removes obstacles from the critical path, reduces development risks, eliminates the white space in pre-clinical drug development, and shortens the pathway to clinical development.

Learn how this partnership improves flexibility for customers, offers dedicated project teams, and enables a bespoke service that is tailored to each development program.